Ligase-based method to detect the polymorphism of warfarin related genes: VKORC1,CYP2C9

Abstract

Abstract: AIM: To establish one ligase-based method to detect the polymorphism of warfarin related genes.METHODS: The multiplex PCR/ ligase detection reaction(LDR) was established to detect warfarin related genes(VKORC1,CYP2C9) polymorphisms and 207 Han Chinese was detected using this method.RESULTS: No CYP2C9^*2(rs1799853)was detected and the frequency of CYP2C9^*3,VKORC1:1173C>T,VKORC1:3730G>A,VKORC1:-1639G>A were 4.35%,　5.8%,　5.31%,　6.76%,respectively . The mutation frequency of rs4086116 which located in the 3^rd intron of CYP2C9 was 10.14%.CONCLUSION: This method is accurate, time-saving and labor-saving. And the detection results of the blood sample consistent with previous results.

Key words: Warfarin, Ligase detection reaction, VKORC1, CYP2C9, Genetic polymorphism

CLC Number:

R973⁺.1

ZHANG Ya-tong, LIANG Xin, HU Xin, LI Ke-xin, YANG Li-ping. Ligase-based method to detect the polymorphism of warfarin related genes: VKORC1,CYP2C9[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(12): 1395-1401.

References

[1] Wadelius M, Pirmohamed M.Pharmacogenetics of warfarin:current status and uture challenges[J]. Pharmacogenomics J, 2006,9(19):1-13.
[2] Higashim K,Veenstrad L,Kondol M,et al.Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy[J].JAMA,2002,287(13):1690-1698.
[3] Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose[J].Blood, 2008 ,112(4):1022-1027.
[4] Rost S,Fregin A,Hunerberg M,et al.Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1:evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfrain[J].Thromb Hacemost,2005, 94(4):780-786.
[5] Yuan H,Chen JJ,Lee MT,et al.A noval functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity[J].Hum Mol Gene,2005,14(134):1745-1751.
[6] Schaeffeler E,Lang T,Zanger UM,et al.High-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLC[J].Clin Chem,2001,47(3):548-555.
[7] 梁欣,张亚同,程刚,等. 基于连接酶反应检测硫唑嘌呤基因多态性及应用[J].中国临床药理学与治疗学,2009,14(11):1281-1285.
[8] Zhu J, Zhang W, Li Y, et al. ARMS test for diagnosis of CYP2C9 and VKORC1 mutation in patients with pulmonary embolism in Han Chinese[J]. Pharmacogenomics,2010,11(1):113-119.
[9] You JH, Wong RS, Waye MM, et al. Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients[J]. J Thromb Thrombolysis,2010 Jun 29. [Epub ahead of print].
[10] Wang TL.Genetic factors contribute to patient-specific warfarin dose for Han Chinese[J].Clin Chim Acta,2008,396(1/2):76-79.

[1]	LIU Xiumei, GUO Qianqian, FANG Yuan, CHEN Nan, QI Qi. Pharmaceutical care of patients with antithrombotic therapy after transjugular intrahepatic portal shunt [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 556-560.
[2]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[3]	WU Yuanzhu, LIU Jun, YANG Kui, PENG Jing, LUAN Jiajie, WEI Jun, ZHANG Dafa, SONG Shuai, YUAN Xiaolong, WANG Zhongfang, ZHANG Nianbao, XIE Dan, JIANG Peng, FAN Jie. Distribution of CYP2C9*3 and VKORC1-1639G>A gene polymorphism in Anhui Han population and their influence on the stable dose of warfarin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 652-659.
[4]	LIAN Jinfang, LIU Yiwei, LIN Cuihong, HUANG Pinfang, LIN Rongfang. Comparison of prediction accuracy between warfarin PPK/PD model and multiple regression dose models [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 267-273.
[5]	ZHANG Jinhua, LIU Maobai, CAI Mingzhi, ZHENG Yingli, LAO Haiyan, XIANG Qian, DU Liping, ZHU Zhu, DONG Jing, ZUO Xiaocong, LI Xingang, SHANG Dewei, CHEN Bing, YE Yanrong, WANG Yuzhu, GAO Jianjun, ZHANG Jian, CHEN Wansheng, XIE Haitang, JIAO Zheng. Model informed precision dosing of warfarin: China expert consensus report (2022 version) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1201-1212.
[6]	WEN Dusu, WANG Yi, SUN Jianjun. Comparison of Bayesian method and multiple linear regression method in predicting warfarin dose model [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 33-38.
[7]	LIN Rongfang, ZHENG Weiwei, LIU Yiwei, LIN Cuihong, WANG Changlian, HUANG Pinfang. Correlation of infliximab related genetic polymorphism, serum trough concentration and efficacy in patients with Crohn's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1000-1006.
[8]	ZHAI Yu, YANG Jin. Effects of dietary vitamin K on the stability of warfarin anticoagulation therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 709-715.
[9]	LI Ling, ZHAO Huijia, CHEN Binyao, LIU Xiaohong, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, YUE Jiang, WU Jianguo, YE Qifa. Relevance of CYP2R1 genetic polymorphism and individual therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1053-1059.
[10]	CHEN Binyao, LI Ling, ZHAO Huijia, LIU Xiaohong, QI Zhenhua, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, DONG Li, YUE Jiang, YE Qifa. Relevance of CYP1B1 genetic polymorphism and individual therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1309-1316.
[11]	ZHOU Yuan, LU Xueling, ZHAO Jun, ZHANG Li, YANG Huanjie，WANG Ning. Polymorphism distribution of rs316019 of SLC22A2 in the Uygur population of Xinjiang [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 287-293.
[12]	WANG Shiqi, HU Huawen, CHEN Xiaomin, WANG Jian, YE Honghua. Effects of different intensities of warfarin on patients with coronary atherosclerotic heart disease complicated with atrial fibrillation: a comparative study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1410-1414.
[13]	YANG Rui, XU Haisha, ZHANG Zanling, QU Jian, LI Juan, PENG Shiqi, DAI Yuxin, QU Qiang. Effect of drug interaction on anticoagulant strength of warfarin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1426-1431.
[14]	LI Haigang, FAN Rong, MA Ning, TANG Jing, LIAO Hongchun, ZHENG Xiahui. Research progress on pharmacokinetics factors of warfarin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1292-1298.
[15]	LIN Xiuxian, CHEN Dan, ZHAO Qing, CHEN Yao. Genetic research on the incidence of alcoholic liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1309-1314.